GSK plc

10/15/2026 | Press release | Distributed by Public on 10/15/2026 08:48

Transaction notification (Form 6-K)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.9482
326.441
d)
Aggregated information
Aggregated volume
Price
N/A (single transaction)
e)
Date of the transaction
2026-10-13
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Maya Martinez-Davis
b)
Position/status
President, US
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.9482
351.842
d)
Aggregated information
Aggregated volume
Price
N/A (single transaction)
e)
Date of the transaction
2026-10-13
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Shobie Ramakrishnan
b)
Position/status
Chief Digital and Technology Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADS')
ISIN: US37733W2044
b)
Nature of the transaction
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$46.9482
724.875
d)
Aggregated information
Aggregated volume
Price
N/A (single transaction)
e)
Date of the transaction
2026-10-13
f)
Place of the transaction
New York Stock Exchange (XNYS)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: October 15, 2026
By:/s/ VICTORIA WHYTE
--------------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GSK plc
GSK plc published this content on October 15, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on October 15, 2026 at 14:48 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]